$CLYM News

Reported Saturday, Climb Bio Reports Initial PrisMN Phase 2 Data Showing 200 mg Budoprutug Delivered 70% Mean PLA2R Antibody Reduction, Immunologic Remission In 5 Of 13 Patients At Week 12 In pMN

Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

Climb Bio And Mabworks Report Phase 1 Data Supporting Quarterly CLYM116/MIL116 Dosing For IgA Nephropathy; Phase 3 Trial Expected In 2027

Deutsche Bank Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $28

Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?

Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing Interval

Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug

Climb Bio To Present New Data For Its CLYM116, Budoprutug Programs Across Three Immune-Mediated Kidney Diseases At American Society Of Nephrology Kidney Week 2026

Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $25

HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $30

B. Riley Securities Reiterates Buy on Climb Bio, Raises Price Target to $30

Why Climb Bio, Up 1,300% Over 17 Months, Just Took A Tumble

Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug

BTIG Maintains Buy on Climb Bio, Raises Price Target to $32

Baird Maintains Outperform on Climb Bio, Raises Price Target to $25

Climb Bio’s Kidney Disease Therapy Gets Support for Extended Dosing Schedule

Climb Bio Shares Rise 17% After Phase 1 CLYM116 Trial Data

Climb Bio to Present at Upcoming Investor Conferences

Climb Bio (CLYM) Advances Phase 2 Trial In China, Is The Valuation Already Priced In?